Speed Meet Efficiency: Biometrik Can Complete Bioequivalence Study of Formulation Standard Amlodipine Faster than Target Requirement

Writer: Ega Astiana Nuzul Wahyuni Editor: Oktaviani Utami Dewi

Depok, September 30, 2024 - PT Biometrik Riset Indonesia has again won the tender for the replacement of local raw materials with the formula standard of Amlodipine from the Ministry of Health of the Republic of Indonesia. This tender was attended by 2 pharmaceutical industries, i.e PT Indofarma Tbk and PT Marin Liza. In June 07th 2024, PT Biometrik signed a tender contract agreement. The target completion of this tender is September 30th 2024, but PT Biometrik has completed it on September 6th, 2024 with very satisfactory results.

Efficiency in tender processes is crucial, PT Biometrik has demonstrated its ability to complete tenders ahead of the target time. PT Biometrik to achieve this remarkable speed while maintaining high standards of quality. One of the primary factors contributing to PT Biometrik’s success is its streamlined internal process, collaborating between various departments, this ensures all necessary information is gathered and analyzed promptly.

PT Biometrik understands that the market is constantly evolving. To maintain its edge, the company embraces a culture of continuous improvement, including improving personnel performance, feedback mechanism, and performance reviews are in lace to identify areas for enhancement and implement best practices.

PT Biometrik’s ability to complete Amlodipine tender faster is a testament to its commitment to efficiency, innovation, and quality. By streamlining processes, leveraging technology, fostering collaboration, and building strong relationship.